Shares of Healthcare sector company Vor Biopharma moved 43.6% today, and are now trading at a price of $6.17. The small-cap stock's daily volume was 2,697,775 compared to its average volume of 102,731. The S&P 500 index returned a -0.2% performance.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is based in Cambridge and has 135 full time employees. Its market capitalization is $238,763,792.
7 analysts are following Vor Biopharma and have set target prices ranging from $4 to $20 per share. On average, they have given the company a rating of buy. At today's prices, VOR is trading -59.61% away from its average analyst target price of $15.29 per share.
Over the last year, VOR shares have gone down by -69.2%, which represents a difference of -53.1% when compared to the S&P 500. The stock's 52 week high is $14.29 per share and its 52 week low is $3.48. Vor Biopharma has averaged free cash flows of $-31,875,750.0 over the last four years, with a mean growth rate of -191.0%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.
